GPR40 agonists for the treatment of type 2 diabetes: Life after 'TAKing' a hit

Diabetes, Obesity and Metabolism

Volumn 17, Issue 7, 2015, Pages 622-629

  Mancini, Arturo D ^a,b   Poitout, V ^a,b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Antidiabetic drug; Beta cell; Insulin secretion; Pharmacology; Seven transmembrane domain receptors

Indexed keywords

FASIGLIFAM; G PROTEIN COUPLED RECEPTOR 40; HEMOGLOBIN A1C; INCRETIN; ANTIDIABETIC AGENT; BENZOFURAN DERIVATIVE; FFAR1 PROTEIN, HUMAN; G PROTEIN COUPLED RECEPTOR; GLUCOSE BLOOD LEVEL; INSULIN; SULFONE; TAK-875;

DRUG DESIGN; ENZYME ACTIVITY; ENZYME MODIFICATION; HORMONE ACTION; HUMAN; INSULIN RELEASE; INSULIN SIGNALING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; AGONISTS; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; DRUG RECALL; GLUCOSE BLOOD LEVEL; METABOLISM; SECRETION (PROCESS);

BENZOFURANS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; RECEPTORS, G-PROTEIN-COUPLED; SAFETY-BASED DRUG WITHDRAWALS; SULFONES;

EID: 84931956985     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12442     Document Type: Review

References (82)

1. Dobbins RL, Chester MW, Daniels MB, McGarry JD, Stein DT. Circulating fatty acids are essential for efficient glucose-stimulated insulin secretion after prolonged fasting in humans. Diabetes 1998; 47: 1613-1618.
2. Stein DT, Esser V, Stevenson BE et al. Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat. J Clin Invest 1996; 97: 2728-2735.
3. Crespin SR, Greenough WB III, Steinberg D. Stimulation of insulin secretion by infusion of free fatty acids. J Clin Invest 1969; 48: 1934-1943.
4. Itoh Y, Kawamata Y, Harada M et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 2003; 422: 173-176.
5. Briscoe CP, Tadayyon M, Andrews JL et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem 2003; 278: 11303-11311.
6. Kotarsky K, Nilsson NE, Olde B, Owman C. Progress in methodology. Improved reporter gene assays used to identify ligands acting on orphan seven-transmembrane receptors. Pharmacol Toxicol 2003; 93: 249-258.
7. Lead GPR40 agonist bites the dust. Nat Rev Drug Discov 2014; 13: 91.
8. Prentki M, Matschinsky FM, Madiraju SR. Metabolic signaling in fuel-induced insulin secretion. Cell Metab 2013; 18: 162-185.
9. Sassmann A, Gier B, Grone HJ, Drews G, Offermanns S, Wettschureck N. The Gq/G11-mediated signaling pathway is critical for autocrine potentiation of insulin secretion in mice. J Clin Invest 2010; 120: 2184-2193.
10. Ferdaoussi M, Bergeron V, Zarrouki B et al. G protein-coupled receptor (GPR)40-dependent potentiation of insulin secretion in mouse islets is mediated by protein kinase D1. Diabetologia 2012; 55: 2682-2692.
11. Wang Z, Thurmond DC. Mechanisms of biphasic insulin-granule exocytosis - roles of the cytoskeleton, small GTPases and SNARE proteins. J Cell Sci 2009; 122: 893-903.
12. Latour MG, Alquier T, Oseid E et al. GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes 2007; 56: 1087-1094.
13. Alquier T, Peyot ML, Latour MG et al. Deletion of GPR40 impairs glucose-induced insulin secretion in vivo in mice without affecting intracellular fuel metabolism in islets. Diabetes 2009; 58: 2607-2615.
14. El-Azzouny M, Evans CR, Treutelaar MK, Kennedy RT, Burant CF. Increased glucose metabolism and glycerolipid formation by fatty acids and GPR40 receptor signaling underlies the fatty acid potentiation of insulin secretion. J Biol Chem 2014; 289: 13575-13588.
15. Shapiro H, Shachar S, Sekler I, Hershfinkel M, Walker MD. Role of GPR40 in fatty acid action on the beta cell line INS-1E. Biochem Biophys Res Commun 2005; 335: 97-104.
16. Itoh Y, Hinuma S. GPR40, a free fatty acid receptor on pancreatic beta cells, regulates insulin secretion. Hepatol Res 2005; 33: 171-173.
17. Schnell S, Schaefer M, Schofl C. Free fatty acids increase cytosolic free calcium and stimulate insulin secretion from beta-cells through activation of GPR40. Mol Cell Endocrinol 2007; 263: 173-180.
18. Salehi A, Flodgren E, Nilsson NE et al. Free fatty acid receptor 1 (FFA(1)R/GPR40) and its involvement in fatty-acid-stimulated insulin secretion. Cell Tissue Res 2005; 322: 207-215.
19. Briscoe CP, Peat AJ, McKeown SC et al. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br J Pharmacol 2006; 148: 619-628.
20. Steneberg P, Rubins N, Bartoov-Shifman R, Walker MD, Edlund H. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab 2005; 1: 245-258.
21. Kebede M, Alquier T, Latour MG, Semache M, Tremblay C, Poitout V. The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes 2008; 57: 2432-2437.
22. Lan H, Hoos LM, Liu L et al. Lack of FFAR1/GPR40 does not protect mice from high-fat diet-induced metabolic disease. Diabetes 2008; 57: 2999-3006.
23. Nagasumi K, Esaki R, Iwachidow K et al. Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes 2009; 58: 1067-1076.
24. Poitout V, Amyot J, Semache M, Zarrouki B, Hagman D, Fontes G. Glucolipotoxicity of the pancreatic beta cell. Biochim Biophys Acta 2010; 1801: 289-298.
25. Kristinsson H, Smith DM, Bergsten P, Sargsyan E. FFAR1 is involved in both the acute and chronic effects of palmitate on insulin secretion. Endocrinology 2013; 154: 4078-4088.
26. Sun P, Wang T, Zhou Y et al. DC260126: a small-molecule antagonist of GPR40 that protects against pancreatic beta-Cells dysfunction in db/db mice. PLoS One 2013; 8: e66744.
27. Zhang X, Yan G, Li Y, Zhu W, Wang H. DC260126, a small-molecule antagonist of GPR40, improves insulin tolerance but not glucose tolerance in obese Zucker rats. Biomed Pharmacother 2010; 64: 647-651.
28. Tan CP, Feng Y, Zhou YP et al. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes 2008; 57: 2211-2219.
29. Pang Z, Wu N, Zhang X et al. GPR40 is partially required for insulin secretion following activation of beta3-adrenergic receptors. Mol Cell Endocrinol 2010; 325: 18-25.
30. Lin DCH, Zhang J, Zhuang R et al. AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in Rodents. PLoS One 2011; 6: e27270.
31. Luo J, Swaminath G, Brown SP et al. A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents. PLoS One 2012; 7: e46300.
32. Tsujihata Y, Ito R, Suzuki M et al. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. J Pharmacol Exp Ther 2011; 339: 228-237.
33. Wagner R, Kaiser G, Gerst F et al. Reevaluation of fatty acid receptor 1 as a drug target for the stimulation of insulin secretion in humans. Diabetes 2013; 62: 2106-2111.
34. Alquier T, Poitout V. GPR40: good cop, bad cop? Diabetes 2009; 58: 1035-1036.
35. Fontes G, Zarrouki B, Hagman DK etal. Glucolipotoxicity age-dependently impairs beta cell function in rats despite a marked increase in beta cell mass. Diabetologia 2010; 53: 2369-2379.
36. Tomita T, Masuzaki H, Iwakura H et al. Expression of the gene for a membrane-bound fatty acid receptor in the pancreas and islet cell tumours in humans: evidence for GPR40 expression in pancreatic beta cells and implications for insulin secretion. Diabetologia 2006; 49: 962-968.
37. Del Guerra S, Bugliani M, D'Aleo V et al. G-protein-coupled receptor 40 (GPR40) expression and its regulation in human pancreatic islets: the role of type 2 diabetes and fatty acids. Nutr Metab Cardiovasc Dis 2010; 20: 22-25.
38. Sunil V, Verma MK, Oommen AM et al. CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients. BMC Pharmacol Toxicol 2014; 15: 19.
39. Burant CF, Viswanathan P, Marcinak J et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2012; 379: 1403-1411.
40. Kaku K, Araki T, Yoshinaka R. Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. Diabetes Care 2013; 36: 245-250.
41. Stoddart LA, Brown AJ, Milligan G. Uncovering the pharmacology of the G protein-coupled receptor GPR40: high apparent constitutive activity in guanosine 5'-O-(3-[35S]thio)triphosphate binding studies reflects binding of an endogenous agonist. Mol Pharmacol 2007; 71: 994-1005.
42. Fujiwara K, Maekawa F, Yada T. Oleic acid interacts with GPR40 to induce Ca2+ signaling in rat islet beta-cells: mediation by PLC and L-type Ca2+ channel and link to insulin release. Am J Physiol Endocrinol Metab 2005; 289: E670-677.
43. Zhao YF, Pei J, Chen C. Activation of ATP-sensitive potassium channels in rat pancreatic beta-cells by linoleic acid through both intracellular metabolites and membrane receptor signalling pathway. J Endocrinol 2008; 198: 533-540.
44. Feng DD, Luo Z, Roh SG et al. Reduction in voltage-gated K+ currents in primary cultured rat pancreatic beta-cells by linoleic acids. Endocrinology 2006; 147: 674-682.
45. Kalwat MA, Thurmond DC. Signaling mechanisms of glucose-induced F-actin remodeling in pancreatic islet beta cells. Exp Mol Med 2013; 45: e37.
46. Reiter E, Ahn S, Shukla AK, Lefkowitz RJ. Molecular mechanism of beta-arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol 2012; 52: 179-197.
47. Whalen EJ, Rajagopal S, Lefkowitz RJ. Therapeutic potential of beta-arrestin- and G protein-biased agonists. Trends Mol Med 2011; 17: 126-139.
48. Wisler JW, Xiao K, Thomsen AR, Lefkowitz RJ. Recent developments in biased agonism. Curr Opin Cell Biol 2014; 27: 18-24.
49. Mancini AD, Poitout V. The fatty acid receptor FFA1/GPR40 a decade later: how much do we know? Trends Endocrinol Metab 2013; 24: 398-407.
50. Lin DC, Guo Q, Luo J et al. Identification and pharmacological characterization of multiple allosteric binding sites on the free Fatty Acid 1 receptor. Mol Pharmacol 2012; 82: 843-859.
51. Srivastava A, Yano J, Hirozane Y et al. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. Nature 2014; 513: 124-127.
52. Hauge M, Vestmar MA, Husted AS, Ekberg JP, Wright MJ, Di Salvo J etal. GPR40 (FFAR1) - Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo. Mol Metab 2015; 4: 3-14.
53. Schroder R, Schmidt J, Blattermann S et al. Applying label-free dynamic mass redistribution technology to frame signaling of G protein-coupled receptors noninvasively in living cells. Nat Protoc 2011; 6: 1748-1760.
54. Sum CS, Tikhonova IG, Neumann S et al. Identification of residues important for agonist recognition and activation in GPR40. J Biol Chem 2007; 282: 29248-29255.
55. Tikhonova IG, Sum CS, Neumann S et al. Bidirectional, iterative approach to the structural delineation of the functional "chemoprint" in GPR40 for agonist recognition. J Med Chem 2007; 50: 2981-2989.
56. Yashiro H, Tsujihata Y, Takeuchi K, Hazama M, Johnson PR, Rorsman P. The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets. J Pharmacol Exp Ther 2012; 340: 483-489.
57. Yabuki C, Komatsu H, Tsujihata Y et al. A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1. PLoS One 2013; 8: e76280.
58. Naik H, Vakilynejad M, Wu J et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. J Clin Pharmacol 2012; 52: 1007-1016.
59. Christiansen E, Hansen SV, Urban C et al. Discovery of TUG-770: a highly potent free fatty acid receptor 1 (FFA1/GPR40) agonist for treatment of type 2 diabetes. ACS Med Chem Lett 2013; 4: 441-445.
60. Gowda N, Dandu A, Singh J et al. Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of diabetes and improves beta cell preservation and function in male ZDF rats. BMC Pharmacol Toxicol 2013; 14: 28.
61. Lane JR, Sexton PM, Christopoulos A. Bridging the gap: bitopic ligands of G-protein-coupled receptors. Trends Pharmacol Sci 2013; 34: 59-66.
62. Edfalk S, Steneberg P, Edlund H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 2008; 57: 2280-2287.
63. Parker HE, Habib AM, Rogers GJ, Gribble FM, Reimann F. Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 2009; 52: 289-298.
64. Liou AP, Lu X, Sei Y et al. The G-protein-coupled receptor GPR40 directly mediates long-chain fatty acid-induced secretion of cholecystokinin. Gastroenterology 2011; 140: 903-912.
65. Xiong Y, Swaminath G, Cao Q et al. Activation of FFA1 mediates GLP-1 secretion in mice. Evidence for allosterism at FFA1. Mol Cell Endocrinol 2013; 369: 119-129.
66. Leifke E, Naik H, Wu J et al. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. Clin Pharmacol Ther 2012; 92: 29-39.
67. Wang Y, Liu JJ, Dransfield PJ et al. Discovery and optimization of potent GPR40 full agonists containing tricyclic spirocycles. ACS Med Chem Lett 2013; 4: 551-555.
68. Flodgren E, Olde B, Meidute-Abaraviciene S, Winzell MS, Ahren B, Salehi A. GPR40 is expressed in glucagon producing cells and affects glucagon secretion. Biochem Biophys Res Commun 2007; 354: 240-245.
69. Wang L, Zhao Y, Gui B et al. Acute stimulation of glucagon secretion by linoleic acid results from GPR40 activation and [Ca2+]i increase in pancreatic islet [alpha]-cells. J Endocrinol 2011; 210: 173-179.
70. Hirasawa A, Itsubo C, Sadakane K et al. Production and characterization of a monoclonal antibody against GPR40 (FFAR1; free fatty acid receptor 1). Biochem Biophys Res Commun 2008; 365: 22-28.
71. Bartoov-Shifman R, Ridner G, Bahar K, Rubins N, Walker MD. Regulation of the gene encoding GPR40, a fatty acid receptor expressed selectively in pancreatic beta cells. J Biol Chem 2007; 282: 23561-23571.
72. Ma D, Lu L, Boneva NB et al. Expression of free fatty acid receptor GPR40 in the neurogenic niche of adult monkey hippocampus. Hippocampus 2008; 18: 326-333.
73. Nakamoto K, Nishinaka T, Matsumoto K et al. Involvement of the long-chain fatty acid receptor GPR40 as a novel pain regulatory system. Brain Res 2012; 1432: 74-83.
74. Nakamoto K, Nishinaka T, Sato N et al. Hypothalamic GPR40 signaling activated by free long chain fatty acids suppresses CFA-induced inflammatory chronic pain. PLoS One 2013; 8: e81563.
75. Boneva NB, Yamashima T. New insights into "GPR40-CREB interaction in adult neurogenesis" specific for primates. Hippocampus 2012; 22: 896-905.
76. Cartoni C, Yasumatsu K, Ohkuri T et al. Taste preference for fatty acids is mediated by GPR40 and GPR120. J Neurosci 2010; 30: 8376-8382.
77. Honore JC, Kooli A, Hamel D et al. Fatty acid receptor Gpr40 mediates neuromicrovascular degeneration induced by transarachidonic acids in rodents. Arterioscler Thromb Vasc Biol 2013; 33: 954-961.
78. Liu JJ, Wang Y, Ma Z et al. Optimization of GPR40 agonists for type 2 diabetes. ACS Med Chem Lett 2014; 5: 517-521.
79. Cornish J, MacGibbon A, Lin JM et al. Modulation of osteoclastogenesis by fatty acids. Endocrinology 2008; 149: 5688-5695.
80. Mieczkowska A, Basle MF, Chappard D, Mabilleau G. Thiazolidinediones induce osteocyte apoptosis by a G protein-coupled receptor 40-dependent mechanism. J Biol Chem 2012; 287: 23517-23526.
81. Wauquier F, Philippe C, Leotoing L et al. The free fatty acid receptor G protein-coupled receptor 40 (GPR40) protects from bone loss through inhibition of osteoclast differentiation. J Biol Chem 2013; 288: 6542-6551.
82. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8: 728-742.